Daily Archives: July 19, 2022
Review | Improving the intensive care experience from the perspectives of different stakeholders.
19 Jul, 2022 | 13:51h | UTC
Review | The ABCDE approach to difficult weaning from venoarterial extracorporeal membrane oxygenation.
19 Jul, 2022 | 13:49h | UTC
Podcast | Diagnosis, prevention, and treatment of Monkeypox.
19 Jul, 2022 | 13:44h | UTCDiagnosis, Prevention, and Treatment of Monkeypox – JAMA
Evidence for Nursing: new evidence and resources.
19 Jul, 2022 | 13:46h | UTCEvidence for Nursing: new evidence and resources – July 2022 – Evidently Cochrane
Who to vaccinate first? A peek at decision-making in a pandemic.
19 Jul, 2022 | 13:40h | UTCWho to vaccinate first? A peek at decision-making in a pandemic – Nature
Podcast | Life-threatening conditions during pregnancy.
19 Jul, 2022 | 13:42h | UTCLife-threatening Conditions During Pregnancy – JAMA
EASL Clinical Practice Guidelines on the management of cystic liver diseases.
19 Jul, 2022 | 13:34h | UTCEASL Clinical Practice Guidelines on the management of cystic liver diseases – Journal of Hepatology
Commentary on Twitter
? @EASLnews Clinical Practice Guidelines on the management of cystic liver diseases‼️
Direct link? https://t.co/qURCSBBRXD@EASLedu @joostphdrenth @torra_roser#LiverTwitter pic.twitter.com/mIIYZyvhQr
— Journal of Hepatology (@JHepatology) June 18, 2022
EASL Clinical Practice Guidelines on sclerosing cholangitis.
19 Jul, 2022 | 13:36h | UTCEASL Clinical Practice Guidelines on sclerosing cholangitis – Journal of Hepatology
Commentary on Twitter
? @EASLnews Clinical Practice Guidelines on the management on sclerosing cholangitis, in press‼️
Direct link? https://t.co/FmtamRPaBX@EASLedu @tomhemmingk@DrCynthiaLevy #LiverTwitter pic.twitter.com/8oRiHt4jKV
— Journal of Hepatology (@JHepatology) June 21, 2022
A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology.
19 Jul, 2022 | 13:38h | UTC
Guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs.
19 Jul, 2022 | 13:30h | UTCRelated:
Rheumatoid arthritis in adults: management – National Institute for Health and Care Excellence
Review and Clinical Guidance | Respiratory events with Terlipressin and albumin in hepatorenal syndrome.
19 Jul, 2022 | 13:32h | UTC
ELN International Recommendations for the diagnosis and management of acute myeloid leukemia in adults.
19 Jul, 2022 | 13:28h | UTC
RCT | Intranasal corticosteroids not beneficial for children with obstructive sleep apnea.
19 Jul, 2022 | 13:27h | UTCA trial of intranasal corticosteroids to treat the childhood obstructive sleep apnea syndrome – CHEST (link to abstract – $ for full-text)
Commentaries:
Intranasal corticosteroids not recommended for most children with OSA: study – Medical Dialogues
Commentary on Twitter
In children with obstructive sleep apnea syndrome, treatment with intranasal corticosteroids did not result in significant polysomnographic, neurobehavioral, and symptom changes compared to placebo, according to research in @journal_CHEST. https://t.co/e4bt4NMv5Z pic.twitter.com/FrIBdoMABf
— American Academy of Sleep Medicine (@AASMorg) July 11, 2022
Systematic Review | Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.
19 Jul, 2022 | 13:25h | UTCAntipsychotics for schizophrenia spectrum disorders with catatonic symptoms – Cochrane Library
RCT | Effect of psychiatric advance directives facilitated by peer workers on compulsory admission among people with mental illness.
19 Jul, 2022 | 13:22h | UTCCommentary: Advance Directives for Psychiatric Care Reduce Compulsory Admissions – Medscape (free registration required)
Commentary on Twitter
A RCT found that psychiatric advance directives facilitated by peer-workers were associated with a significant decrease in compulsory readmission and an increase in recovery outcomes among adults living with SCZ, BP-I or SCZ-Aff. https://t.co/ICcwE1RYyJ #EPA2022
— JAMA Psychiatry (@JAMAPsych) June 6, 2022
RCT | Effect of Dextromethorphan plus Bupropion vs. Bupropion alone in major depressive disorder.
19 Jul, 2022 | 13:19h | UTCEffect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial – American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary: Dextromethorphan-Bupropion Significantly Improves Depression Symptoms, Study Finds – Psychiatry News Alert
Systematic Review | Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
19 Jul, 2022 | 13:24h | UTC
RCT | Efficacy and safety of once-weekly Efpeglenatide monotherapy versus placebo in Type 2 Diabetes.
19 Jul, 2022 | 13:20h | UTC
Management of interstitial lung disease (ILD) in myositis syndromes: a practical guide for clinicians.
19 Jul, 2022 | 13:13h | UTC
Review | Cardiometabolic comorbidities in cancer survivors.
19 Jul, 2022 | 13:17h | UTCCardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review
Nutrition state of science and dementia prevention.
19 Jul, 2022 | 13:11h | UTCCommentary: Improving research on diet and dementia – Keck School of Medicine of USC
M-A of RCTs | Effects of acetaminophen and ibuprofen monotherapy in febrile children.
19 Jul, 2022 | 13:15h | UTC
Cross Sectional Study | Variation in population attributable fraction of dementia associated with potentially modifiable risk factors by race and ethnicity in the US.
19 Jul, 2022 | 13:08h | UTCCommentaries:
12 Risk Factors Linked to Dementia Could Be Modified, Reduce US Cases by 400,000 – HCP Live
Hypertension, obesity, physical inactivity among highest risk factors for dementia – Healio
Commentary on Twitter
Number of people w/dementia is growing worldwide; this article identifies 12 modifiable risk factors accounting for~ 40% of people w/dementia. Hypertension most imp, followed by obesity and physical inactivity. https://t.co/mD5lrqZTyf @JAMANetworkOpen Kudos @PLutsey & team. pic.twitter.com/LG5LjFHqV6
— Harlan Krumholz (@hmkyale) July 7, 2022
In this cross-sectional study, a large fraction of dementia cases in the US were associated with potentially modifiable risk factors, especially for Black and Hispanic individuals. https://t.co/v6g2HPNLpR
— JAMA Network Open (@JAMANetworkOpen) July 6, 2022
Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.
19 Jul, 2022 | 13:00h | UTCLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)
Related:
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Lisocabtagene maraleucel as second-line therapy in adults with R/R large B-cell #lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study https://t.co/NwkfPmVHu0 #lymsm pic.twitter.com/jHj5rFadV2
— The Lancet Oncology (@TheLancetOncol) July 13, 2022
RCT | Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis.
19 Jul, 2022 | 13:06h | UTCTreat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary: TNF inhibitor tapered T2T strategy feasible in PsA and axSpA – medwireNews
Commentary on Twitter
Treat-to-target (#T2T) tapering strategy is an effective and safe alternative to a T2T full dose continuation strategy in patients with #psoriatic #arthritis and axial #spondyloarthritis with stable low disease activity using TNF inhibitorshttps://t.co/YhurbawiTm pic.twitter.com/1jj4zuYkPf
— ARD & RMD Open (@ARD_BMJ) June 18, 2022